RxDoctor Payments Data

Deepthi Gandhiraj, MD

Pulmonary Disease · Yuma, AZNPI 1144621012

Payments from drug & device makers

$6,475in general payments, 2019–2025

Across 41 payments — averaging $157.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Johnson & Johnson$904
  • GSK$160
  • Amgen$125
  • Innovation Technologies Inc$118
  • Actelion Pharmaceuticals US, Inc.$101
  • plus $282 from 10 others

What the payments were for

  • Travel & lodging$1,11817%
  • Food & beverage$85713%
  • Education$4,50069%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,475 in reported general payments places this provider in the 60th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$261,117
Medicare patients
169
Services billed
9,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter166$133,803
Spiriva RespimatTiotropium Bromide78$51,911
Breztri AerosphereBudesonide/Glycopyr/Formoterol60$44,776
Incruse ElliptaUmeclidinium Bromide84$34,588
Breo ElliptaFluticasone/Vilanterol35$16,569
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$14,369
Wixela InhubFluticasone Propion/Salmeterol49$4,388
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$2,949
Albuterol Sulfate HfaAlbuterol Sulfate113$2,771
Azithromycin47$313
Levofloxacin30$160
Prednisone68$147
Montelukast Sodium21$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta$160$199,330305 claims
Boehringer IngelheimSpiriva Respimat$21$51,91178 claims
AstraZenecaBreztri Aerosphere$83$44,77660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →